Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Small Cell Lung Carcinoma 3Multiple Myeloma 2Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Carcinoma, Merkel Cell 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × lorvotuzumab mertansine × Clear all
NCT00991562 2014-11-21

IMGN901 in Combination With Lenalidomide and Dexamethasone

ImmunoGen, Inc.

Phase 1 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00346255 2013-04-23

IMGN901

ImmunoGen, Inc.

Phase 1 Completed
37 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡